Laser Treatment for Epilepsy: SLAH Review

This explainer summarizes a review of laser treatment for epilepsy in people with drug-resistant mesial temporal lobe epilepsy.

Source: Neurologia i neurochirurgia polska

Summary

What was studied

This review examined MRI-guided laser treatment for drug-resistant mesial temporal lobe epilepsy, which involves structures deep within the temporal lobe. It focused on selective laser amygdalohippocampotomy (SLAH), a procedure that uses laser heat to destroy targeted tissue involved in seizures.

The authors reviewed published treatment experiences rather than reporting a new clinical trial. They discussed seizure control, safety, and how SLAH compares with anterior temporal lobectomy, an open operation that removes part of the temporal lobe.

What they found

Across many published series, approximately 50–60% of patients achieved Engel Class I status, meaning freedom from disabling seizures, though not necessarily every seizure symptom. Seizure-freedom rates were generally lower than those reported after anterior temporal lobectomy in comparable patient groups.

The review reported a more favorable safety profile for SLAH, including fewer problems affecting memory and language, fewer visual field deficits, and fewer complications around surgery. Advances in imaging, targeting methods, intracranial monitoring, and real-time temperature mapping have improved procedural precision and safety. SLAH may also be repeated if needed.

Limits of the evidence

Most evidence came from retrospective studies, which look back at existing records, and from individual treatment centers. The abstract does not give the number of studies or patients reviewed, follow-up lengths, or numerical rates for safety outcomes. Prospective, ideally comparative studies are needed to better establish long-term seizure control, durability of benefits, and the best criteria for selecting patients. Surgical techniques and outcome reporting also need greater standardization.

For families and caregivers

This review describes a trade-off: SLAH is less invasive and may carry fewer risks to memory, language, and the visual field, but it generally has lower seizure-freedom rates than anterior temporal lobectomy. It may be particularly relevant when the risk of cognitive decline after open surgery is a concern or when a less invasive approach is preferred. The reported 50–60% result does not predict an individual person's outcome.

What to watch next

Prospective studies, ideally comparing procedures directly, are needed to clarify long-term seizure outcomes, durability of treatment effects, and which patients are most likely to benefit. Greater standardization of surgical techniques and outcome reporting is also needed.

Terms in this summary

Drug-resistant epilepsy: Epilepsy in which seizures continue despite treatment with seizure medicines.
Mesial temporal lobe epilepsy (MTLE): Epilepsy in which seizures start in structures deep within the temporal lobe of the brain.
MRI-guided laser interstitial thermal therapy (MRIgLITT): A procedure that uses MRI scans to guide and monitor laser heating of targeted brain tissue.
Selective laser amygdalohippocampotomy (SLAH): A laser procedure targeting the amygdala and hippocampus, structures involved in some temporal lobe seizures.
Engel Class I: A surgical outcome category indicating freedom from disabling seizures; some seizure symptoms, such as auras, may still occur.
Anterior temporal lobectomy (ATL): An open operation that removes part of the temporal lobe to treat seizures.
Visual field deficit: Loss of vision in part of the area a person can normally see.